Recruiting
Ovarian cancer recurrent
RecruitingRinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy
Registered drugNo placebo
Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy
Registered drugNo placebo
- Disease:Ovarian cancer recurrent
- Substances:BevacizumabHUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
Countries:
Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Genmab A/S
